宜明昂科：药品审评中心批准IMM0306治疗复发/难治性滤泡性淋巴瘤的III期

Core Viewpoint - The approval of the III phase clinical research protocol for IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma marks a significant advancement in innovative therapies for this condition [1] Group 1 - The company has received approval from the National Medical Products Administration (NMPA) for the clinical study [1] - The study focuses on relapsed/refractory follicular lymphoma, indicating a targeted approach to a specific patient population [1] - This development accelerates the progress of innovative treatments in the field of oncology [1]